ABBV · News · 20260922N

China Trial Data Inquiry

AbbVie Inc. · 2026-09-22 · Importance 31 · Surprise 42

A U.S. House committee requested information from AbbVie concerning data protection and ethics at the company's clinical-trial sites in China. The inquiry creates potential regulatory, compliance, and clinical-development risk, although the digest provides no allegation, subpoena amount, deadline, or identified financial provision. The report did not state whether any investigation or enforcement action had begun.

Key facts

• A House committee has requested information from AbbVie regarding data protection and ethics at its clinical trial sites in China. source